AAN 2021 | Satralizumab in patients with NMOSD and concomitant autoimmune diseases

Anthony Traboulsee, MD, University of British Columbia Hospital, Vancouver, Canada, shares the findings of an investigation into the safety and efficacy of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) patients with concomitant autoimmune diseases (CAIDs). In the SAKura studies (SAkuraSky, NCT02028884; SAkuraStar, NCT02073279), satralizumab was shown to effectively reduce relapse risk in patients with NMOSD. Since NMOSD commonly occurs with CAIDs, an analysis was conducted to independently assess the population of patients with CAIDs in the SAKura studies. It was shown that satralizumab had a comparable safety and efficacy profile in these patients to the overall study populations, whether given as a monotherapy or in combination with baseline immunosuppressants. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.